Lucentis' main patents are not due to expire in Europe until next year, but Samsung Bioepis and Biogen are now poised to roll out the drug as soon the intellectual property on the drug lapses.

Outlook Therapeutics首席财务官兼临时首席执行官Lawrence Kenyon对ONS-5010治疗湿性AMD的潜力表示乐观,他引用了NORSE临床试验中安全性结果的一致性。公司计划在2025年第一季度内在美国重新提交ONS-5010的生物制品许可申请 (BLA)。

It cites an “anticompetitive agreement” in the market for Lucentis active ingredient, the anti-VEGF antibody ranibizumab. Specifically, the ACGM claims that the companies entered into a ...

ISELIN, N.J. - Outlook Therapeutics, Inc. (NASDAQ:OTLK), a clinical-stage biopharmaceutical company with a current market capitalization of $52 million, reported at the Hawaiian Eye and Retina 2025 ...

Background: To identify differences between Ranibizumab and Aflibercept in treatment-naïve patients with neovascular age-related macular degeneration (nvAMD) in a real-life clinical setting ...

Outlook Therapeutics (OTLK) has completed the analysis of the complete 12-week safety and efficacy results for NORSE EIGHT, the second of two clinical trials evaluating ONS-5010 in wet age-related ...

While the wet AMD market is highly competitive, with established therapies such as Eylea, Vabysmo, and Lucentis dominating, Opthea Limited (NASDAQ:OPT) is positioning sozinibercept as a ...

Bs: Bevasiranib sodium; CABERNET: A study of Strontium 90 β Radiation With Lucentis to Treat Age-Related Macular Degeneration; CARBON: Combination of Bevasiranib and Lucentis Therapy in Wet AMD ...

Background: Neovascular age-related macular degeneration (AMD) has a poor prognosis if left untreated, frequently resulting in legal blindness. Ranibizumab is approved for treating neovascular AMD.

Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon’s biosimilar candidate to Eylea ® 1 Agreement builds on the proven and successful collaboration ...